Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
7.6.2021 18:40:00 EEST | Business Wire | Press release
Press release
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the appointment of Sébastien BESSY as Chief Operating Marketing and Business Officer.
As of June 8, 2021, Sébastien BESSY will be responsible for the global deployment and coordination of the international strategy related to Valbiotis’ marketing and commercial development in order to support the growth of the Company, and strengthen and develop strategic alliances.
Furthermore, Sébastien BESSY, as a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since 2014, will become a member of the Board of Directors as of his appointment.
Sébastien PELTIER, CEO, Chairman of the Board of Directors, comments: "We are delighted to welcome Sébastien BESSY to the Valbiotis Board of Directors. He will drive the Company's ambition at a pivotal time as we prepare the market launch of our first four active substances in development. Sébastien BESSY has in-depth knowledge of the challenges of the healthcare sector with over 20 years of experience in Consumer Healthcare at international pharmaceutical groups. His highly strategic expertise in key markets is a crucial asset that will enable Valbiotis to accelerate its momentum in the future and to strengthen and develop alliances. With our multitarget active substances, we aim to transform the health experiences of millions of people around the world. The appointment of Sébastien BESSY is perfectly in tune with this objective, and the ability to establish our products thanks to high level market expertise will be a decisive asset in shaping Valbiotis' success."
Sébastien BESSY is an expert in the Consumer Healthcare sector, having held various marketing and innovation positions at major pharmaceutical companies over the past 20 years. He has unique international experience, both operational and strategic, in consumer marketing and product innovation, particularly in Europe, Asia including China, North America and Latin America.
During his last 6 years at Ipsen, Sébastien BESSY held the positions of Vice-President Global Marketing & Portfolio Strategy Consumer Healthcare and Vice-President Global Strategic Operations Consumer Healthcare. Prior to joining Ipsen, Sébastien BESSY previously held the positions of Managing Director Europe at Biofortis, a subsidiary of Mérieux Nutrisciences, Global Director of "Probiotic Platform" Innovation at Merck Consumer Healthcare, Global Strategic Marketing Director at Merck Consumer Healthcare and Global Marketing Manager at Reckitt Benckiser.
Sébastien BESSY is a graduate of ISC Paris and began his career at Sanofi Aventis.
Sébastien BESSY adds: ‘I am delighted to join Valbiotis at this time of accelerated development. Throughout my career, in different markets around the world, I have been committed to bringing more and more innovations to patients. I am very excited to join this dynamic company with a clear mission and commitment to develop a new class of plant-based health nutrition products that address unmet needs in the prevention and control of metabolic diseases. Worldwide, 39% of adults are overweight or obese1, a major risk factor for premature death2, often associated with metabolic disorders such as elevated fasting blood glucose, dyslipidemia or high blood pressure3. Hundreds of millions of people around the world are affected. Valbiotis' pipeline and R&D platform represent a source of value for future alliances and a potential for rapid expansion, which will need to be supported by a commercial organization capable of targeting these significant markets, key to our priorities. As a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since its creation, I have been able to follow the progress made in just a few years and to appreciate the strength of the strategy implemented, to which I intend to devote all my energy.’
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com.
1 World Health Organization, Global Health Observatory, www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-overweight-among-adults-bmi-greaterequal-25-(crude-estimate)-(-) (consulted on May 27, 2021).
2World Health Organization, www.emro.who.int/fr/noncommunicable-diseases/causes/unhealthy-diets.html
(consulted on May 27, 2021).
3 The IDF consensus worldwide definition of the metabolic syndrome, International Diabetes Federation, 2006.
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005510/en/
Contact information
Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
media@valbiotis.com
Financial communication / Actifin
Stéphane Ruiz
+33 1 56 88 11 14
sruiz@actifin.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer16.2.2026 11:00:00 EET | Press release
K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep expertise in leading complex, multi-market organisations and has successfully scaled $800M+ P&Ls, working closely with boards, sponsors, and executive leadership teams across the USA, UK, Europe, the Middle East, and APAC. Most recently, Srinivas served as Chief Business Officer and a member of the Executive Council at LTIMindtree, where he was accountable for growth acceleration, market expansion, strategic customer relationships, and operating performance across a highly complex regional footprint. During his tenure, he played a pivotal role in strengthening go-to-market execution, driving margin
Klarna Launches on Google Pay in the UK16.2.2026 10:00:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, is now available on Google Pay in the UK. Google Pay users in the U.K. can choose Klarna’s interest-free payment options at checkout. Raji Behal, Head of Western and Southern Europe, UK & Ireland at Klarna, said, “We’re really excited to bring Klarna’s fair, flexible and interest-free payment options to Google Pay users. This is a big moment for us and a major step towards our goal of being available at every checkout, everywhere. Together with Google, we’re making it easier than ever for millions of shoppers to choose Klarna and pay in a smarter, more transparent way — all from their phone.” Lisa Yokoyama, Director of Product Management at Google Paysaid: "Expanding our collaboration with Klarna to the U.K. underscores our goal to empower more people with the flexibility to pay how they choose. With people shopping on Google over a billion times a day, this broader footprint provides even more checkout options to help bus
Italy Sees Economic Boost From the Opening Weekend of the Olympic Winter Games Milano Cortina 202616.2.2026 10:00:00 EET | Press release
Visa, the Official Payment Technology Partner of the Olympic and Paralympic Winter Games, today released new data revealing consumer spending patterns in the Winter Games host locations1 during the opening weekend of the Olympic Winter Games Milano Cortina 2026. VisaNet data analysed by Visa Consulting & Analytics (VCA) shows the positive impact that Milano Cortina 2026 is having on commerce: Overseas Visa cardholders visits rose by more than 60%, with the largest share of visitors coming from the U.S. (+160% year-on-year), followed by China, Brazil, Canada and Japan. In Europe, Visa cardholders from Germany represent the largest share of visitors (31% year-on-year increase), followed by Switzerland, France and the UK. International Visa cardholders spent more than in the previous year, with the U.S. leading the year-on-year growth with a 125% increase in their spending, followed by Canada and Switzerland. Visitors from Germany, China and the U.S. ranked as the top spenders, with an av
New ECCO data show subcutaneous (SC) infliximab (Remsima ™ SC) effectively recaptures and maintains disease control after drug holiday16.2.2026 09:00:00 EET | Press release
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102.1 The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held from February 18-21 in Stockholm, Sweden. “As immunogenicity is the most significant concern when restarting treatment with infliximab after an interruption, these results suggest that treatment persistence was maintained even in patients with immunogenicity,” said Dr. Marla Dubinsky, Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine at Mount Sinai. “It's reassuring to see that not only can we effectively recapture disease control with a convenient subcutaneous option, but that t
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom